k141_36106_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.9	224	233	231	5.00e-62	192
k141_36106_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.2	224	233	228	3.68e-61	190
k141_36106_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.2	227	233	232	4.74e-60	187
k141_36106_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.2	227	233	232	4.74e-60	187
k141_36106_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.3	230	233	233	1.11e-58	184
k141_36106_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	41.8	232	233	235	3.36e-58	183
k141_36106_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.5	220	233	219	1.17e-57	181
k141_36106_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	233	232	1.74e-57	181
k141_36106_2	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.6	230	233	232	6.99e-57	179
k141_36106_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.9	227	233	231	1.36e-56	179
k141_183516_2	SARG|gb|AAC75314.1|ARO:3003578|pmrF	29.7	313	326	322	3.34e-32	121
k141_183516_3	SARG|P42332	38.0	229	311	306	6.86e-44	151
k141_183516_3	SARG|ABB80128	38.0	229	311	306	1.35e-43	150
k141_183516_3	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	37.6	229	311	306	1.90e-43	150
k141_183516_3	SARG|gi|510143239|gb|AGN36970.1|	37.6	229	311	313	2.25e-43	150
k141_183516_3	SARG|gi|542061059|gb|ERI11611.1|	38.4	229	311	316	4.77e-43	149
k141_183516_3	SARG|AAD21213	37.6	229	311	306	5.26e-43	149
k141_183516_3	SARG|gi|447195835|ref|WP_001273091.1|	38.1	231	311	306	7.38e-43	148
k141_183516_3	SARG|gi|447195836|ref|WP_001273092.1|	37.7	231	311	306	2.04e-42	147
k141_183516_3	SARG|gi|500194536|ref|WP_011867743.1|	37.7	220	311	306	5.64e-42	146
k141_183516_3	SARG|ZP_04081918	37.2	231	311	306	7.91e-42	145
k141_151662_32	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	41.9	681	649	703	4.64e-160	475
k141_183557_8	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.6	686	660	703	8.28e-87	285
k141_183557_9	SARG|gb|APB03219.1|ARO:3003986|TaeA	45.6	642	597	648	2.26e-180	523
k141_183557_9	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	537	597	655	4.97e-67	229
k141_183557_9	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	537	597	655	4.97e-67	229
k141_183557_9	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	537	597	655	9.57e-67	228
k141_183557_9	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	537	597	655	1.84e-66	228
k141_183557_9	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	537	597	655	6.83e-66	226
k141_183557_9	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	537	597	655	6.83e-66	226
k141_183557_9	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	537	597	655	6.83e-66	226
k141_183557_9	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.9	537	597	655	6.83e-66	226
k141_183557_9	SARG|GQ205627.2.gene1.p01	31.0	525	597	525	9.53e-66	223
k141_143911_12	SARG|gi|488053456|ref|WP_002124853.1|	30.9	320	367	309	3.68e-46	159
k141_143911_12	SARG|gi|488067981|ref|WP_002139378.1|	31.2	317	367	309	1.02e-45	157
k141_143911_12	SARG|gi|507050365|ref|WP_016121371.1|	30.6	320	367	309	1.02e-45	157
k141_143911_12	SARG|gi|488068784|ref|WP_002140181.1|	30.9	317	367	309	1.42e-45	157
k141_143911_12	SARG|gi|488130770|ref|WP_002201978.1|	31.5	317	367	309	2.00e-45	157
k141_143911_12	SARG|gi|507055561|ref|WP_016126482.1|	30.9	320	367	309	2.80e-45	156
k141_143911_12	SARG|gi|507023808|ref|WP_016095885.1|	30.9	317	367	309	2.80e-45	156
k141_143911_12	SARG|gi|447057509|ref|WP_001134765.1|	31.5	317	367	309	5.50e-45	155
k141_143911_12	SARG|P42332	32.2	317	367	306	7.15e-45	155
k141_143911_12	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.2	317	367	306	7.15e-45	155
k141_143911_14	ResF|mre(A)_1_U92073_1	31.5	302	300	310	9.98e-34	124
k141_143911_14	SARG|gb|AAB64408.1|ARO:3007050|mreA	31.5	302	300	311	1.02e-33	124
k141_12534_6	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	45.6	158	160	159	2.16e-38	127
k141_12534_10	SARG|gb|AAK76136.1|ARO:3000025|patB	36.1	559	636	588	2.52e-101	319
k141_12534_10	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.2	549	636	664	6.37e-90	291
k141_12534_10	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.0	613	636	579	1.33e-87	283
k141_12534_10	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.5	613	636	579	1.40e-86	280
k141_12534_10	SARG|gi|1033217078|gb|OAR27197.1|	31.3	614	636	601	1.24e-78	260
k141_12534_10	SARG|gb|CDO61516.1|ARO:3003949|efrB	38.0	384	636	362	3.65e-78	251
k141_12534_10	SARG|gi|493394434|ref|WP_006350564.1|	30.1	627	636	602	6.73e-78	258
k141_12534_10	SARG|gi|664556405|ref|WP_031071225.1|	30.9	622	636	602	3.56e-77	256
k141_12534_10	SARG|gi|497748188|ref|WP_010062372.1|	30.0	619	636	605	3.81e-77	256
k141_12534_10	SARG|gi|664180077|ref|WP_030714054.1|	30.2	619	636	605	3.81e-77	256
k141_12534_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.9	549	579	575	1.98e-112	346
k141_12534_11	SARG|gb|AAK76137.1|ARO:3000024|patA	36.3	571	579	564	5.42e-109	337
k141_12534_11	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.8	569	579	582	1.08e-68	231
k141_12534_11	SARG|gb|AAK76136.1|ARO:3000025|patB	29.4	523	579	588	1.75e-66	226
k141_12534_11	SARG|gi|748767925|ref|WP_040019608.1|	37.6	367	579	623	1.82e-66	226
k141_12534_11	SARG|AF170880.4.gene1.p01	30.9	540	579	615	5.81e-66	225
k141_12534_11	SARG|gi|558888514|ref|WP_023543283.1|	30.6	540	579	615	8.07e-66	224
k141_12534_11	SARG|gi|944009777|ref|WP_055601444.1|	30.0	573	579	628	2.00e-65	224
k141_12534_11	SARG|gi|664556405|ref|WP_031071225.1|	29.4	572	579	602	2.34e-65	223
k141_12534_11	SARG|gi|1045390184|ref|WP_065479071.1|	30.2	536	579	605	4.80e-65	222
k141_135991_26	SARG|gi|1035706844|ref|WP_064548272.1|	33.3	111	942	648	5.58e-07	52.4
k141_183811_6	SARG|gi|313638554|gb|EFS03703.1|	28.9	463	490	453	4.98e-68	224
k141_183811_6	SARG|gi|313614636|gb|EFR88215.1|	29.8	460	490	453	6.29e-64	213
k141_183811_6	SARG|gi|984518628|emb|CUM21384.1|	31.2	330	490	341	9.47e-53	180
k141_183811_6	SARG|gi|313619623|gb|EFR91268.1|	33.5	242	490	237	1.66e-41	147
k141_183811_6	SARG|gi|313609598|gb|EFR85124.1|	33.2	229	490	226	3.38e-39	140
k141_183811_6	SARG|HE999704.1.gene1126.p01	28.3	311	490	337	6.76e-36	135
k141_183811_6	SARG|gi|441473784|emb|CCQ23538.1|	28.6	311	490	336	3.32e-35	133
k141_183811_6	SARG|HE999704.1.gene1125.p01	46.2	93	490	107	1.60e-22	91.3
k141_28496_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.4	225	281	307	6.28e-32	119
k141_28496_4	SARG|gi|500465078|gb|EOP76697.1|	28.1	224	281	306	3.53e-26	103
k141_28496_4	SARG|gi|542061059|gb|ERI11611.1|	28.8	229	281	316	8.03e-26	102
k141_28496_4	SARG|gi|500448961|gb|EOP61695.1|	26.8	224	281	306	1.31e-25	102
k141_28496_4	SARG|P42332	26.4	220	281	306	2.53e-25	101
k141_28496_4	SARG|gi|447195835|ref|WP_001273091.1|	26.1	226	281	306	4.86e-25	100
k141_28496_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	25.9	220	281	306	6.75e-25	100
k141_28496_4	SARG|gi|447195836|ref|WP_001273092.1|	26.1	226	281	306	6.75e-25	100
k141_28496_4	SARG|gi|510143239|gb|AGN36970.1|	25.9	220	281	313	7.54e-25	100
k141_28496_4	SARG|ABB80128	25.9	220	281	306	9.36e-25	99.8
k141_60491_4	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.4	222	406	451	2.18e-25	106
k141_60491_4	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.6	233	406	392	2.67e-24	102
k141_60491_4	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.9	216	406	885	5.97e-18	85.1
k141_60491_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.4	231	229	232	3.70e-47	154
k141_60491_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.4	231	229	232	3.70e-47	154
k141_60491_5	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.6	228	229	231	4.54e-45	149
k141_60491_5	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.0	234	229	230	2.48e-44	147
k141_60491_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.2	229	229	231	5.09e-44	146
k141_60491_5	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	228	229	231	5.09e-44	146
k141_60491_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.8	230	229	229	9.60e-44	145
k141_60491_5	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	228	229	231	1.43e-43	145
k141_60491_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.8	233	229	239	1.78e-43	145
k141_60491_5	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	228	229	231	2.02e-43	145
k141_24752_5	SARG|gi|505177635|ref|WP_015364737.1|	21.1	375	460	451	3.03e-22	97.8
k141_112194_2	SARG|gb|AAD01868.1|ARO:3002867|dfrF	45.5	154	159	164	5.66e-42	136
k141_112194_2	SARG|CAL48457	32.5	166	159	183	6.19e-29	103
k141_112194_2	SARG|gb|AAO04716.1|ARO:3002865|dfrC	36.5	126	159	161	3.90e-25	93.6
k141_112194_2	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	36.5	126	159	161	5.51e-25	93.2
k141_80465_15	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.5	875	805	1033	2.29e-30	127
k141_80465_15	SARG|gb|AEY83581|ARO:3000510|mupB	22.5	875	805	1033	2.29e-30	127
k141_80465_15	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.3	727	805	1024	3.36e-25	111
k141_80465_15	SARG|gb|CAA53189|ARO:3000521|mupA	22.3	727	805	1024	3.36e-25	111
k141_80465_15	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	711	805	1024	4.43e-25	110
k141_80465_15	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	711	805	1024	4.43e-25	110
k141_80465_15	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.5	699	805	1107	1.04e-16	84.0
k141_80465_15	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.5	699	805	1107	1.04e-16	84.0
k141_188260_6	megares|MEG_4193|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	43.5	154	159	152	2.60e-40	132
k141_188260_6	ResF|nimI_1_FJ940887_1	43.5	154	159	165	3.81e-40	132
k141_188260_6	megares|MEG_4192|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	42.9	154	159	154	3.91e-40	131
k141_188260_6	megares|MEG_4190|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	42.9	154	159	152	5.22e-40	131
k141_188260_6	megares|MEG_4191|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	43.5	154	159	152	5.22e-40	131
k141_188260_6	ResF|nimI_1_FJ940889_1	42.9	154	159	165	5.40e-40	131
k141_188260_6	ResF|nimI_1_FJ940884_1	42.9	154	159	165	7.65e-40	131
k141_188260_6	ResF|nimI_1_FJ940886_1	43.5	154	159	165	7.65e-40	131
k141_188260_6	NCBI|WP_005812825.1|1|1|nimJ|nimJ|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimJ|AMR|nitroimidazole	41.2	153	159	165	1.08e-39	130
k141_188260_6	NCBI|WP_087312253.1|1|1|nimG|nimG||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimG|AMR|nitroimidazole	40.4	161	159	164	6.00e-39	129
k141_148329_8	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.9	778	872	1024	9.02e-68	243
k141_148329_8	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	778	872	1024	9.02e-68	243
k141_148329_8	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	778	872	1024	3.05e-67	241
k141_148329_8	SARG|gb|CAA53189|ARO:3000521|mupA	24.9	778	872	1024	3.05e-67	241
k141_20808_20	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	34.3	216	387	392	1.11e-27	111
k141_20808_20	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	31.2	215	387	364	5.79e-25	103
k141_20808_20	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	31.2	215	387	364	5.79e-25	103
k141_20808_20	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.8	314	387	361	1.95e-24	102
k141_20808_20	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.9	305	387	382	2.64e-22	96.3
k141_20808_20	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.9	305	387	382	2.64e-22	96.3
k141_20808_20	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	31.3	214	387	364	5.50e-22	95.1
k141_20808_20	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	31.3	214	387	364	5.50e-22	95.1
k141_20808_20	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	22.6	292	387	367	1.95e-21	93.6
k141_20808_20	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.0	204	387	368	9.14e-21	91.7
k141_20808_21	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	37.7	223	226	231	4.09e-42	141
k141_20808_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.2	218	226	219	4.65e-41	138
k141_20808_21	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.9	222	226	219	1.99e-36	126
k141_20808_21	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	222	226	219	7.87e-36	125
k141_20808_21	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	222	226	220	8.08e-36	125
k141_20808_21	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	222	226	220	1.14e-35	124
k141_20808_21	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	222	226	220	1.77e-34	121
k141_20808_21	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.7	219	226	223	3.79e-34	120
k141_20808_21	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.2	228	226	225	3.69e-31	113
k141_20808_21	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.2	228	226	225	3.69e-31	113
k141_48989_2	SARG|gi|1004359922|gb|AMP42228.1|	28.6	455	601	639	7.64e-30	123
k141_48989_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.8	454	601	629	1.33e-28	119
k141_48989_2	ResF|tet(O/W)_3_AM889120_1	27.8	454	601	639	1.38e-28	119
k141_48989_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.8	454	601	629	2.36e-28	119
k141_48989_2	ResF|tet(O/W)_4_AM889121_1	27.8	454	601	639	2.46e-28	119
k141_48989_2	SARG|ACI02041	28.1	455	601	639	3.28e-28	118
k141_48989_2	SARG|ABN80187	28.1	455	601	640	3.29e-28	118
k141_48989_2	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.8	454	601	629	5.61e-28	117
k141_48989_2	SARG|AAY62597	28.1	455	601	639	5.84e-28	117
k141_48989_2	ResF|tet(O/W)_5_AM889122_1	27.8	454	601	639	5.84e-28	117
k141_4726_4	SARG|ZP_02952732	29.5	139	824	652	1.48e-09	60.5
k141_4726_4	SARG|L20800.gene.p01	29.5	139	824	652	1.48e-09	60.5
k141_4726_4	SARG|ZP_02632674	29.5	139	824	660	1.49e-09	60.5
k141_4726_4	SARG|NP_348076	28.8	139	824	652	2.56e-09	59.7
k141_4726_4	SARG|YP_002850805	28.1	139	824	652	5.84e-09	58.5
k141_80597_5	SARG|gb|AAK76136.1|ARO:3000025|patB	35.8	472	483	588	6.81e-97	303
k141_80597_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.0	473	483	664	2.71e-94	298
k141_80597_5	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.2	338	483	362	1.44e-86	269
k141_80597_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.8	476	483	582	2.07e-80	259
k141_80597_5	SARG|gi|944152509|ref|WP_055644808.1|	33.3	480	483	616	2.73e-77	252
k141_80597_5	SARG|gi|944009777|ref|WP_055601444.1|	33.8	480	483	628	3.54e-77	252
k141_80597_5	SARG|gi|860594225|ref|WP_048475168.1|	32.7	490	483	620	1.60e-76	250
k141_80597_5	SARG|gi|772774655|ref|WP_045322518.1|	33.1	477	483	620	1.60e-76	250
k141_80597_5	SARG|gi|496018010|ref|WP_008742581.1|	32.8	478	483	623	2.39e-76	250
k141_80597_5	SARG|gi|497748188|ref|WP_010062372.1|	32.8	478	483	605	3.17e-76	249
k141_104867_23	SARG|gi|694085087|ref|WP_032429904.1|	25.6	199	456	646	3.36e-11	64.3
k141_104867_23	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	27.0	204	456	550	2.04e-09	58.5
k141_104867_23	SARG|U82085.gene.p01	24.2	194	456	552	8.28e-09	56.6
k141_104867_23	ResF|poxtA-Ef_1_WP094899500.1_1	26.0	173	456	538	3.09e-07	51.6
k141_104867_23	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.0	173	456	543	3.10e-07	51.6
k141_104867_23	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.0	173	456	543	3.10e-07	51.6
k141_104867_23	SARG|gb|APB03219.1|ARO:3003986|TaeA	20.9	258	456	648	5.87e-07	50.8
k141_104867_23	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.6	172	456	542	1.25e-06	49.7
k141_104867_23	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	25.6	172	456	544	1.25e-06	49.7
k141_168357_5	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	25.5	693	678	641	7.44e-41	157
k141_168357_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	48.2	249	255	255	4.38e-82	245
k141_168357_6	SARG|YP_002850060	43.4	221	255	648	1.91e-59	197
k141_168357_6	SARG|gi|696368937|ref|WP_032943949.1|	43.0	221	255	648	1.41e-58	195
k141_168357_6	SARG|gi|851913025|ref|WP_048215946.1|	43.0	221	255	648	1.41e-58	195
k141_168357_6	SARG|gi|489930965|ref|WP_003834285.1|	43.0	221	255	648	1.41e-58	195
k141_168357_6	SARG|gi|493734654|ref|WP_006683876.1|	39.3	257	255	648	1.96e-58	195
k141_168357_6	SARG|gi|495736522|ref|WP_008461101.1|	43.0	221	255	648	2.73e-58	194
k141_168357_6	SARG|gi|696361545|ref|WP_032936694.1|	43.0	221	255	648	2.73e-58	194
k141_168357_6	SARG|gi|489936909|ref|WP_003840216.1|	43.0	221	255	648	2.73e-58	194
k141_168357_6	SARG|gi|507079862|ref|WP_016150620.1|	43.0	221	255	648	2.73e-58	194
k141_168357_7	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	48.5	103	111	341	5.27e-28	103
k141_53166_5	SARG|YP_002937728	64.8	287	287	289	6.99e-129	367
k141_53166_5	SARG|ZP_03958019	64.0	278	287	317	2.01e-125	359
k141_53166_5	SARG|ZP_04528247	61.9	278	287	279	1.91e-114	330
k141_53166_5	SARG|YP_002929946	55.7	282	287	282	2.07e-102	299
k141_53166_5	SARG|ZP_03949893	56.9	274	287	288	5.47e-99	291
k141_53166_5	SARG|ZP_04433866	56.6	274	287	288	3.13e-98	289
k141_53166_5	SARG|ZP_03984017	56.2	274	287	288	6.29e-98	288
k141_53166_5	SARG|ZP_03945515	52.3	279	287	291	2.97e-89	266
k141_53166_5	SARG|ZP_03938934	51.3	277	287	288	5.42e-89	265
k141_53166_5	SARG|ZP_03916453	51.6	287	287	290	8.19e-89	265
k141_176686_1	SARG|AF155139.2.gene4.p01	31.8	195	323	293	9.50e-28	108
k141_176686_1	SARG|CAB61224	32.4	188	323	297	2.64e-25	102
k141_176686_1	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	31.5	197	323	299	1.38e-24	100
k141_176686_1	SARG|gi|1025843957|ref|WP_063576302.1|	36.6	134	323	287	1.56e-24	99.8
k141_176686_1	SARG|AAY52007	37.9	132	323	294	4.65e-24	98.6
k141_176686_1	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	37.9	132	323	296	6.64e-24	98.2
k141_176686_1	SARG|gi|503204183|ref|WP_013438844.1|	30.2	189	323	303	3.73e-23	96.3
k141_176686_1	SARG|ACP19238	29.6	189	323	296	8.76e-23	95.1
k141_176686_1	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	29.6	189	323	296	8.76e-23	95.1
k141_176686_1	SARG|AAA65958	29.6	189	323	303	9.77e-23	95.1
k141_5078_2	NCBI|WP_003126779.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	46.8	47	369	190	3.00e-07	49.3
k141_137005_3	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.4	356	453	674	3.39e-11	64.3
k141_137005_3	SARG|gb|BAI83385.1|ARO:3003440|mecB	24.1	344	453	674	1.04e-10	62.8
k141_156538_2	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.8	260	651	1033	2.18e-09	59.7
k141_156538_2	SARG|gb|AEY83581|ARO:3000510|mupB	25.8	260	651	1033	2.18e-09	59.7
k141_156538_5	SARG|AAV80410	30.8	637	873	651	2.35e-88	293
k141_156538_5	SARG|L42544.gene.p01	30.8	637	873	651	4.54e-88	292
k141_156538_5	SARG|YP_002850805	32.3	625	873	652	1.25e-87	291
k141_156538_5	SARG|ZP_02952732	32.0	625	873	652	1.73e-86	288
k141_156538_5	SARG|ZP_02632674	32.0	625	873	660	2.09e-86	288
k141_156538_5	SARG|L20800.gene.p01	32.0	625	873	652	3.35e-86	287
k141_156538_5	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.8	617	873	641	1.31e-82	277
k141_156538_5	SARG|AAZ79478	29.8	617	873	657	1.88e-82	277
k141_156538_5	SARG|NP_348076	31.6	627	873	652	2.33e-82	277
k141_156538_5	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.7	617	873	654	1.66e-79	269
k141_77365_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.1	228	256	231	5.20e-57	181
k141_77365_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	228	256	232	3.10e-53	171
k141_77365_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	256	232	3.10e-53	171
k141_77365_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.3	229	256	232	4.94e-52	168
k141_77365_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.6	228	256	231	1.08e-50	164
k141_77365_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.6	232	256	235	1.36e-49	162
k141_77365_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.4	230	256	233	3.62e-49	160
k141_77365_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.2	228	256	231	6.81e-49	160
k141_77365_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.7	228	256	231	9.62e-49	159
k141_77365_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.2	228	256	231	1.36e-48	159
k141_77365_3	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.5	228	482	382	6.49e-22	96.3
k141_77365_3	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.5	228	482	382	6.49e-22	96.3
k141_77365_3	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.8	214	482	367	2.72e-20	91.3
k141_77365_3	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.8	214	482	368	2.74e-20	91.3
k141_77365_3	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	26.5	219	482	357	9.88e-17	80.5
k141_77365_3	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	26.5	219	482	357	9.88e-17	80.5
k141_77365_23	SARG|gb|ABA71733.1|ARO:3002972|vanTG	37.7	369	383	712	7.99e-74	242
k141_77365_23	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	36.3	369	383	712	4.38e-72	237
k141_77365_23	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	34.4	369	383	711	3.60e-60	205
k141_77365_23	SARG|FJ872411.1.gene43.p01	32.0	366	383	702	2.28e-59	203
k141_77365_23	SARG|gi|498467693|ref|WP_010773049.1|	33.2	364	383	700	5.93e-59	202
k141_77365_23	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.2	374	383	700	7.60e-55	191
k141_77365_23	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.8	373	383	700	2.69e-53	186
k141_77365_23	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	33.5	373	383	706	5.49e-53	186
k141_77365_23	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	35.5	330	383	700	2.58e-52	184
k141_77365_23	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	29.9	381	383	366	3.06e-51	174
k141_149060_3	CARD|gb|WKR28567.1|ARO:3007678|IreK	32.6	592	711	718	5.34e-86	285
k141_149060_5	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	36.7	332	366	349	1.33e-55	184
k141_149060_5	SARG|AXY65402.1	36.3	328	366	357	3.22e-55	184
k141_149060_5	SARG|gb|AIX48090.1|ARO:3004599|clcD	36.4	332	366	349	3.69e-55	183
k141_149060_5	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	36.4	332	366	349	5.18e-55	183
k141_149060_5	SARG|gb|BAH45481.1|ARO:3002815|clbB	37.4	337	366	343	3.42e-54	181
k141_149060_5	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.9	332	366	349	4.64e-52	175
k141_149060_5	SARG|VXQ21601.1	34.6	338	366	344	5.74e-52	175
k141_149060_5	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	35.4	353	366	416	5.86e-52	177
k141_149060_5	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	36.6	331	366	379	6.88e-52	176
k141_149060_5	SARG|AJ249217.gene.p01	34.9	332	366	349	1.28e-51	174
k141_37212_1	SARG|Q08425	21.3	582	582	641	8.53e-23	101
k141_37212_1	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	21.3	582	582	657	8.85e-23	101
k141_37212_1	SARG|Z21523.gene.p01	21.3	582	582	657	8.85e-23	101
k141_37212_1	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	21.3	582	582	654	1.17e-22	101
k141_37212_1	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	21.3	582	582	670	1.21e-22	101
k141_37212_1	SARG|AAB51122	21.3	582	582	670	1.21e-22	101
k141_37212_1	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	21.0	582	582	641	1.50e-22	100
k141_37212_1	SARG|AAZ79478	21.0	582	582	657	1.56e-22	100
k141_37212_1	SARG|Q52360	21.3	582	582	641	2.00e-22	100
k141_37212_1	SARG|P70882	20.9	583	582	641	4.67e-22	99.4
k141_73379_3	SARG|gb|AAK76136.1|ARO:3000025|patB	35.4	577	608	588	4.65e-116	357
k141_73379_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	48.9	352	608	362	2.26e-109	332
k141_73379_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	515	608	664	5.17e-103	325
k141_73379_3	SARG|gi|497748188|ref|WP_010062372.1|	32.9	581	608	605	9.07e-93	296
k141_73379_3	SARG|gi|947982677|ref|WP_056642336.1|	33.7	594	608	626	1.53e-92	296
k141_73379_3	SARG|gi|639892676|ref|WP_024755698.1|	33.7	594	608	631	1.74e-92	296
k141_73379_3	SARG|gi|1033217078|gb|OAR27197.1|	33.4	581	608	601	3.17e-92	295
k141_73379_3	SARG|gi|944152509|ref|WP_055644808.1|	33.8	585	608	616	3.30e-92	295
k141_73379_3	SARG|gi|516795764|ref|WP_018105258.1|	33.5	579	608	601	1.72e-91	293
k141_73379_3	SARG|AF170880.4.gene1.p01	33.3	579	608	615	2.44e-91	293
k141_73379_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	42.4	526	777	575	5.66e-132	403
k141_73379_4	SARG|gb|AAK76137.1|ARO:3000024|patA	37.7	493	777	564	4.11e-112	351
k141_73379_4	SARG|gi|917229923|ref|WP_051836635.1|	31.9	517	777	620	3.90e-66	230
k141_73379_4	SARG|gi|917155568|ref|WP_051762280.1|	32.2	491	777	620	1.41e-65	228
k141_73379_4	SARG|gi|917166849|ref|WP_051773561.1|	32.0	491	777	620	5.12e-65	227
k141_73379_4	SARG|gi|827013130|ref|WP_047175495.1|	30.3	505	777	603	9.61e-65	226
k141_73379_4	SARG|gi|930482089|ref|WP_054228897.1|	36.4	360	777	599	1.22e-64	225
k141_73379_4	SARG|gi|985844137|ref|WP_060895163.1|	36.4	360	777	599	1.22e-64	225
k141_73379_4	SARG|gi|951183771|ref|WP_057661487.1|	29.9	505	777	603	1.83e-64	225
k141_73379_4	SARG|gi|1045390184|ref|WP_065479071.1|	29.8	504	777	605	1.90e-64	225
k141_73379_17	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	34.4	218	288	293	7.20e-34	124
k141_73379_17	SARG|gi|542061059|gb|ERI11611.1|	35.0	220	288	316	4.44e-33	122
k141_73379_17	SARG|gi|500194536|ref|WP_011867743.1|	34.4	212	288	306	2.05e-30	115
k141_73379_17	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.0	217	288	307	1.57e-26	104
k141_73379_17	ResF|poxtA-Ef_1_WP094899500.1_1	26.1	207	288	538	2.70e-06	47.4
k141_73379_17	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.1	207	288	543	2.71e-06	47.4
k141_73379_17	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.1	207	288	543	2.71e-06	47.4
k141_53438_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	62.1	377	459	1162	1.26e-151	459
k141_53438_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	59.7	417	459	1186	3.17e-150	456
k141_53438_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	59.7	417	459	1186	3.17e-150	456
k141_37266_3	SARG|gi|1001720867|ref|WP_061274204.1|	43.0	221	233	648	1.35e-55	186
k141_37266_3	SARG|gi|1035706844|ref|WP_064548272.1|	41.0	234	233	648	1.35e-55	186
k141_37266_3	SARG|gi|495736522|ref|WP_008461101.1|	42.5	221	233	648	3.63e-55	185
k141_37266_3	SARG|gi|746253210|ref|WP_039301529.1|	42.5	221	233	648	3.63e-55	185
k141_37266_3	SARG|gi|1035670474|ref|WP_064517458.1|	41.5	234	233	648	3.63e-55	185
k141_37266_3	SARG|gi|1035717981|ref|WP_064557480.1|	43.0	221	233	648	5.06e-55	185
k141_37266_3	SARG|gi|736472622|ref|WP_034494292.1|	41.5	234	233	648	7.04e-55	184
k141_37266_3	SARG|gi|895981299|ref|WP_049056431.1|	42.1	221	233	648	2.64e-54	183
k141_37266_3	SARG|gi|823281237|ref|WP_047037467.1|	42.1	221	233	648	2.64e-54	183
k141_37266_3	SARG|gi|895967513|ref|WP_049046752.1|	42.1	221	233	648	2.64e-54	183
k141_49565_4	NCBI|WP_063856783.1|1|1|vanXY-G2|vanXY-G2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2|AMR|glycopeptide	33.5	257	400	254	1.02e-39	141
k141_49565_4	NCBI|WP_063856782.1|1|1|vanXY-G|vanXY-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G|AMR|glycopeptide	33.9	257	400	254	2.90e-38	137
k141_49565_4	NCBI|WP_107309513.1|1|1|vanY-M|vanY-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-M|AMR|glycopeptide	34.6	266	400	287	6.87e-36	132
k141_49565_4	SARG|FJ349556.1.gene4.p01	36.0	250	400	233	9.80e-35	127
k141_116554_15	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.1	793	942	1024	1.42e-117	383
k141_116554_15	SARG|gb|CAA53189|ARO:3000521|mupA	31.1	793	942	1024	1.42e-117	383
k141_116554_15	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	31.1	793	942	1024	1.98e-117	382
k141_116554_15	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.1	793	942	1024	1.98e-117	382
k141_116554_15	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	30.5	827	942	1033	1.20e-109	362
k141_116554_15	SARG|gb|AEY83581|ARO:3000510|mupB	30.5	827	942	1033	1.20e-109	362
k141_97664_6	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	534	534	655	7.68e-72	240
k141_97664_6	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	534	534	655	1.07e-71	240
k141_97664_6	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	534	534	655	1.07e-71	240
k141_97664_6	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	534	534	655	1.07e-71	240
k141_97664_6	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	534	534	655	7.84e-71	238
k141_97664_6	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	534	534	655	1.09e-70	237
k141_97664_6	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	534	534	655	1.09e-70	237
k141_97664_6	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	534	534	655	1.09e-70	237
k141_97664_6	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	534	534	655	1.09e-70	237
k141_97664_6	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	534	534	655	1.09e-70	237
k141_2441_6	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.5	235	353	648	4.53e-19	87.4
k141_2441_6	SARG|gb|AEA37904.1|ARO:3003112|lsaC	25.7	202	353	492	4.44e-14	72.0
k141_113026_3	SARG|gb|AAC75314.1|ARO:3003578|pmrF	29.1	320	318	322	2.79e-32	121
k141_152684_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	65.2	233	233	233	5.18e-111	317
k141_152684_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	64.3	235	233	235	4.54e-110	315
k141_152684_9	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	65.2	233	233	232	3.02e-105	302
k141_152684_9	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	64.8	233	233	232	3.02e-105	302
k141_152684_9	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	65.2	233	233	232	4.29e-105	302
k141_152684_9	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	64.8	233	233	232	1.23e-104	301
k141_152684_9	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	64.8	233	233	232	1.74e-104	300
k141_152684_9	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	64.4	233	233	232	1.00e-103	298
k141_152684_9	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	65.4	231	233	239	1.48e-102	296
k141_152684_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	63.8	232	233	231	4.56e-102	294
k141_152684_10	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	51.9	316	446	361	7.37e-95	289
k141_152684_10	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	51.9	316	446	361	7.37e-95	289
k141_152684_10	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	56.7	277	446	354	1.67e-94	288
k141_152684_10	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	51.6	316	446	361	5.87e-94	286
k141_152684_10	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	51.6	316	446	361	5.87e-94	286
k141_152684_10	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	53.3	287	446	364	2.04e-92	283
k141_152684_10	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	53.3	287	446	364	2.04e-92	283
k141_152684_10	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	58.7	259	446	352	1.58e-91	280
k141_152684_10	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	58.7	259	446	376	6.62e-91	279
k141_152684_10	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	58.7	259	446	376	6.62e-91	279
k141_152684_11	SARG|gi|403023847|gb|EJY36064.1|	58.0	176	225	200	6.65e-71	214
k141_152684_11	SARG|gi|403219412|emb|CCJ27774.1|	58.0	176	225	268	2.01e-70	215
k141_152684_11	SARG|gi|452996227|gb|AGG19410.1|	58.0	176	225	252	3.48e-70	214
k141_152684_11	SARG|gi|488259314|ref|WP_002330522.1|	58.0	176	225	268	5.72e-70	214
k141_152684_11	SARG|gi|1036536100|emb|SAM71699.1|	58.0	176	225	268	5.72e-70	214
k141_152684_11	SARG|KF823969.1.gene3.p01	58.0	176	225	268	5.72e-70	214
k141_152684_11	SARG|gi|452996213|gb|AGG19398.1|	56.8	176	225	268	9.26e-69	211
k141_152684_11	SARG|gi|498515090|ref|WP_010815297.1|	56.8	176	225	268	9.26e-69	211
k141_152684_11	SARG|Q47746	56.3	176	225	268	3.72e-68	209
k141_152684_11	SARG|gb|ABA71729.1|ARO:3002959|vanYG1	50.0	180	225	279	9.42e-55	175
k141_152684_19	SARG|gi|515720450|ref|WP_017153050.1|	36.2	138	133	210	5.75e-13	62.0
k141_152684_19	SARG|gi|670466162|ref|WP_031414939.1|	41.4	70	133	206	2.86e-12	60.1
k141_152684_19	SARG|gi|1028848471|ref|WP_064017434.1|	41.4	70	133	206	1.07e-11	58.5
k141_152684_19	SARG|AF155139.2.gene5.p01	33.8	130	133	206	2.05e-10	55.1
k141_105848_6	SARG|AAA22075	32.3	223	292	340	1.89e-19	85.9
k141_105848_6	ResF|erm(A)_3_EU348758_1	29.1	182	292	243	5.87e-17	77.4
k141_105848_6	megares|MEG_2786|Drugs|MLS|23S_rRNA_methyltransferases|ERMA_1	30.4	158	292	198	1.75e-15	72.4
k141_105848_6	SARG|AF319779.2.orf0.gene.p01	29.5	183	292	266	1.92e-15	73.6
k141_105848_6	SARG|ZP_04543635	29.1	182	292	266	9.15e-15	71.6
k141_105848_6	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	28.8	139	292	304	7.10e-10	57.8
k141_137463_10	SARG|gi|1028100561|ref|WP_063856696.1|	45.0	347	357	349	1.23e-102	305
k141_137463_10	SARG|gi|752682279|ref|WP_041330231.1|	45.2	347	357	349	2.47e-102	304
k141_137463_10	SARG|DQ212986.1.gene8.p01	43.8	349	357	349	5.19e-99	296
k141_137463_10	SARG|gi|405945042|pdb|4FU0|A	43.8	349	357	357	6.69e-99	296
k141_137463_10	SARG|gi|765411304|ref|WP_044689514.1|	43.8	349	357	349	1.04e-98	295
k141_137463_10	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	44.8	362	357	366	2.52e-98	295
k141_137463_10	SARG|AAF71281	43.6	349	357	349	2.95e-98	294
k141_137463_10	SARG|gi|749574464|ref|WP_040203371.1|	42.6	357	357	343	1.20e-90	274
k141_137463_10	SARG|ACP19236	42.3	357	357	343	6.78e-90	272
k141_137463_10	SARG|gb|KTE89608.1|ARO:3003723|vanI	41.9	363	357	348	7.93e-90	272
k141_137463_15	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.4	228	230	255	1.15e-45	151
k141_137463_15	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.9	222	230	579	6.37e-25	101
k141_137463_15	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.9	222	230	579	2.19e-24	99.8
k141_137463_15	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.2	202	230	362	2.85e-22	92.4
k141_137463_15	SARG|gb|AAK76137.1|ARO:3000024|patA	29.3	225	230	564	2.82e-18	82.0
k141_137463_15	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.5	220	230	664	3.84e-16	75.9
k141_137463_15	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	233	230	588	6.76e-16	75.1
k141_137463_15	SARG|gb|AGN74946|ARO:3003749|salA	26.7	221	230	541	4.51e-14	69.7
k141_137463_15	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	36.9	84	230	568	1.66e-09	56.2
k141_137463_15	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	29.3	82	230	550	8.19e-07	48.1
k141_69681_4	SARG|gb|AAS79458.1|ARO:3001302|chrB	39.2	186	277	280	1.02e-27	107
k141_69681_4	SARG|gb|AAD12162.1|ARO:3001299|tlrB	32.8	259	277	280	1.04e-26	104
k141_69681_4	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	32.8	259	277	280	1.04e-26	104
k141_69681_4	megares|MEG_4107|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	30.2	242	277	283	1.12e-23	96.3
k141_37518_2	SARG|CAB61224	31.7	262	338	297	3.70e-31	118
k141_37518_2	SARG|ACP19238	31.7	262	338	296	1.36e-29	114
k141_37518_2	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	31.7	262	338	296	1.36e-29	114
k141_37518_2	SARG|AAA65958	31.7	262	338	303	1.57e-29	114
k141_37518_2	SARG|gi|503204183|ref|WP_013438844.1|	31.7	262	338	303	1.57e-29	114
k141_37518_2	SARG|gi|309385867|gb|ADO66792.1|	31.7	262	338	305	1.63e-29	114
k141_37518_2	SARG|gi|816206780|gb|AKE81065.1|	31.7	262	338	327	2.44e-29	114
k141_37518_2	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	35.5	203	338	296	2.63e-29	113
k141_37518_2	SARG|AAY52007	42.4	144	338	294	6.79e-29	112
k141_37518_2	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	42.4	144	338	299	7.48e-29	112
k141_37518_3	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.7	249	382	356	5.53e-19	86.3
k141_37518_3	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.7	249	382	356	5.53e-19	86.3
k141_37518_3	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.3	249	382	346	2.29e-18	84.3
k141_37518_3	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.6	257	382	355	6.19e-18	83.2
k141_37518_3	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.6	257	382	355	6.19e-18	83.2
k141_37518_3	SARG|ACM47285	29.6	257	382	363	6.62e-18	83.2
k141_37518_3	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.8	248	382	356	8.44e-18	82.8
k141_37518_3	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.2	272	382	355	7.50e-16	77.0
k141_37518_3	SARG|BAE96115	27.2	272	382	355	7.50e-16	77.0
k141_37518_3	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	27.5	211	382	209	2.92e-10	58.5
k141_37518_7	SARG|gi|542061059|gb|ERI11611.1|	33.7	309	359	316	1.94e-45	157
k141_37518_7	SARG|P42332	33.0	309	359	306	3.17e-44	153
k141_37518_7	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	33.0	309	359	306	3.17e-44	153
k141_37518_7	SARG|gi|510143239|gb|AGN36970.1|	33.0	309	359	313	3.77e-44	153
k141_37518_7	SARG|gi|507055561|ref|WP_016126482.1|	31.0	316	359	309	4.79e-44	153
k141_37518_7	SARG|gi|488068784|ref|WP_002140181.1|	32.4	312	359	309	4.79e-44	153
k141_37518_7	SARG|gi|446026113|ref|WP_000103968.1|	32.1	312	359	306	6.23e-44	152
k141_37518_7	SARG|gi|447057510|ref|WP_001134766.1|	32.1	312	359	309	6.71e-44	152
k141_37518_7	SARG|ABB80128	33.0	309	359	306	8.73e-44	152
k141_37518_7	SARG|gi|488053456|ref|WP_002124853.1|	31.0	316	359	309	9.41e-44	152
k141_37518_14	SARG|YP_002850217	31.9	279	311	660	5.11e-39	144
k141_37518_14	SARG|gi|1002399350|ref|WP_061382108.1|	31.2	279	311	660	7.00e-39	144
k141_37518_14	SARG|gi|851965596|ref|WP_048234849.1|	31.5	279	311	660	1.80e-38	142
k141_37518_14	SARG|gi|851935911|ref|WP_048224705.1|	30.5	279	311	660	1.19e-37	140
k141_37518_14	SARG|gi|507086291|ref|WP_016157032.1|	30.8	279	311	660	1.19e-37	140
k141_37518_14	SARG|gi|757799830|ref|WP_043017032.1|	31.2	279	311	660	1.19e-37	140
k141_37518_14	SARG|gi|489931383|ref|WP_003834702.1|	31.2	279	311	660	1.19e-37	140
k141_37518_14	SARG|gi|489117806|ref|WP_003027650.1|	30.8	279	311	660	4.17e-37	139
k141_37518_14	SARG|gi|696375142|ref|WP_032949690.1|	30.8	279	311	660	4.17e-37	139
k141_37518_14	SARG|gi|696369048|ref|WP_032944060.1|	30.5	279	311	660	5.71e-37	138
k141_26090_2	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	49.0	871	858	1162	1.04e-264	767
k141_26090_2	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	47.1	870	858	1186	3.05e-249	728
k141_26090_2	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	47.1	870	858	1186	3.05e-249	728
k141_113399_9	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	25.8	182	388	314	1.28e-12	67.0
k141_113399_9	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	27.5	204	388	322	1.90e-11	63.5
k141_113399_13	SARG|AAV80410	29.2	367	607	651	5.76e-33	133
k141_113399_13	SARG|L42544.gene.p01	29.4	367	607	651	1.39e-32	132
k141_113399_13	SARG|YP_002850805	27.8	392	607	652	6.20e-31	127
k141_113399_13	SARG|NP_348076	26.2	393	607	652	1.50e-29	122
k141_113399_13	SARG|AJ514254.gene.p01	44.9	136	607	640	6.07e-29	120
k141_113399_13	SARG|ABG21123	38.5	179	607	639	1.44e-27	116
k141_113399_13	SARG|AAK17952	38.5	179	607	639	1.07e-26	114
k141_113399_13	SARG|ABN11268	38.5	179	607	639	1.07e-26	114
k141_113399_13	SARG|AAY63943	38.0	179	607	639	1.43e-26	113
k141_113399_13	SARG|gi|446614384|ref|WP_000691730.1|	38.0	179	607	639	1.43e-26	113
k141_113399_16	SARG|gb|AAC75271.1|ARO:3003952|yojI	29.1	196	310	547	7.02e-14	70.9
k141_113399_16	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	23.9	201	310	578	1.04e-11	64.3
k141_113399_16	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.7	255	310	655	8.30e-07	49.3
k141_113399_16	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.7	255	310	655	8.30e-07	49.3
k141_113399_16	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	6.07e-06	46.6
k141_113399_16	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	8.06e-06	46.2
k141_113399_16	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	8.06e-06	46.2
k141_113399_16	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	8.06e-06	46.2
k141_113399_16	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	8.06e-06	46.2
k141_113399_16	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.4	255	310	655	8.06e-06	46.2
k141_65982_8	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.2	213	580	467	9.60e-20	91.3
k141_65982_8	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.3	218	580	885	3.64e-11	65.1
k141_65982_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.4	220	225	219	8.17e-56	176
k141_65982_9	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	225	219	4.41e-38	130
k141_65982_9	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	224	225	220	4.53e-38	130
k141_65982_9	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	224	225	220	4.53e-38	130
k141_65982_9	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	229	225	231	6.06e-38	130
k141_65982_9	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	225	219	6.22e-38	130
k141_65982_9	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	224	225	220	6.39e-38	130
k141_65982_9	SARG|ZP_02848503	35.6	225	225	221	6.57e-38	130
k141_65982_9	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	230	225	231	1.70e-37	129
k141_65982_9	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.6	229	225	231	1.70e-37	129
k141_81658_4	SARG|gi|581672381|gb|EVQ77821.1|	29.3	157	246	394	5.04e-06	45.8
k141_81658_4	SARG|gi|587321226|gb|EWW03298.1|	29.3	157	246	413	5.16e-06	45.8
k141_81658_4	SARG|gi|580336413|gb|EVD62957.1|	29.3	157	246	478	5.49e-06	45.8
k141_81658_4	SARG|YP_001569068	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|686379454|ref|WP_031899389.1|	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|727749040|ref|WP_033861720.1|	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|686337405|ref|WP_031882938.1|	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|686300118|ref|WP_031865761.1|	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|486352750|ref|WP_001590778.1|	29.3	157	246	488	5.53e-06	45.8
k141_81658_4	SARG|gi|686196490|ref|WP_031807261.1|	29.3	157	246	488	5.53e-06	45.8
k141_153065_2	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.3	525	641	655	4.03e-115	357
k141_153065_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.3	525	641	655	5.67e-115	357
k141_153065_2	SARG|gb|AKA86814|ARO:3003746|optrA	37.3	525	641	655	5.67e-115	357
k141_153065_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	6.17e-114	354
k141_153065_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	8.68e-114	354
k141_153065_2	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	8.68e-114	354
k141_153065_2	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	1.22e-113	353
k141_153065_2	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	1.22e-113	353
k141_153065_2	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	1.22e-113	353
k141_153065_2	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.1	525	641	655	1.22e-113	353
k141_113562_3	SARG|gb|AAG04750.1|ARO:3004077|PmpM	24.3	408	459	477	2.98e-14	73.6
k141_113562_3	SARG|gi|488374619|ref|WP_002444004.1|	21.1	431	459	452	4.66e-12	66.6
k141_113562_3	SARG|gi|505177635|ref|WP_015364737.1|	22.7	415	459	451	6.17e-12	66.2
k141_113562_3	SARG|YP_302230	22.3	403	459	451	5.96e-11	63.2
k141_113562_3	NCBI|AAG27731.1|1|1|norM-Burk|norM-Burk|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_NorM|AMR|efflux	21.2	419	459	462	6.11e-11	63.2
k141_113562_3	SARG|gi|446573710|ref|WP_000651056.1|	21.4	416	459	451	1.05e-10	62.4
k141_113562_3	SARG|gi|446573715|ref|WP_000651061.1|	21.6	416	459	451	1.05e-10	62.4
k141_113562_3	SARG|ZP_04679156	21.9	421	459	451	1.39e-10	62.0
k141_113562_3	SARG|gi|565830932|ref|WP_023914633.1|	21.9	416	459	451	2.45e-10	61.2
k141_113562_3	SARG|gi|686390606|ref|WP_031905637.1|	21.4	416	459	451	2.45e-10	61.2
k141_177729_9	SARG|gb|AAC75314.1|ARO:3003578|pmrF	29.5	325	327	322	1.14e-36	133
k141_93972_4	SARG|AAN28721	43.1	72	390	108	2.90e-13	64.7
k141_93972_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.6	224	237	219	4.61e-50	162
k141_93972_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	226	237	232	5.37e-49	159
k141_93972_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.5	228	237	229	9.84e-49	159
k141_93972_6	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.2	223	237	220	1.21e-47	155
k141_93972_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.1	227	237	228	4.29e-47	154
k141_93972_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.4	225	237	231	1.86e-46	153
k141_93972_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.8	229	237	232	2.70e-46	152
k141_93972_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.8	229	237	232	2.70e-46	152
k141_93972_6	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	223	237	219	3.73e-46	152
k141_93972_6	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	223	237	220	3.84e-46	152
k141_93972_7	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	234	497	381	4.05e-30	120
k141_93972_7	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	234	497	381	4.05e-30	120
k141_93972_7	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	234	497	381	3.60e-29	117
k141_93972_7	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	234	497	381	3.60e-29	117
k141_93972_7	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	26.2	202	497	357	9.80e-22	95.5
k141_93972_7	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	26.2	202	497	357	9.80e-22	95.5
k141_93972_7	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.2	265	497	365	4.82e-21	93.6
k141_93972_7	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	22.6	265	497	370	4.11e-20	90.9
k141_93972_7	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.7	93	497	233	1.07e-09	57.8
k141_93972_7	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	26.7	86	497	233	1.45e-09	57.4
k141_113776_1	SARG|gi|488374619|ref|WP_002444004.1|	22.8	272	464	452	5.00e-07	50.8
k141_138287_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.3	369	402	575	4.80e-62	208
k141_138287_11	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	24.5	413	402	579	4.30e-30	120
k141_138287_11	SARG|gb|AAC74000.1|ARO:3003950|msbA	23.5	395	402	582	3.68e-29	118
k141_138287_11	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	23.9	415	402	579	1.22e-28	116
k141_138287_11	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.7	358	402	574	2.24e-25	107
k141_138287_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.2	219	402	362	8.40e-24	100
k141_138287_11	SARG|gi|695842130|ref|WP_032755430.1|	22.0	400	402	603	1.15e-23	102
k141_138287_11	SARG|gi|505420018|ref|WP_015607120.1|	22.0	400	402	603	1.55e-23	101
k141_138287_11	SARG|gi|662129758|ref|WP_030081404.1|	21.1	399	402	605	9.61e-22	96.3
k141_138287_11	SARG|gi|928900436|ref|WP_053931243.1|	21.7	374	402	600	1.28e-21	95.9
k141_26681_1	SARG|gi|754927849|ref|WP_042284850.1|	35.1	328	1005	648	1.87e-49	185
k141_26681_1	SARG|gi|555268367|ref|WP_023249730.1|	38.6	293	1005	648	6.14e-49	184
k141_26681_1	SARG|gi|1027935297|ref|WP_063809363.1|	38.6	293	1005	648	6.14e-49	184
k141_26681_1	SARG|gi|803568669|ref|WP_046077412.1|	34.7	317	1005	648	8.26e-49	183
k141_26681_1	SARG|gi|446110352|ref|WP_000188207.1|	34.7	317	1005	648	8.26e-49	183
k141_26681_1	SARG|YP_002382193	34.7	317	1005	648	8.26e-49	183
k141_26681_1	SARG|gi|803575554|ref|WP_046081557.1|	34.7	317	1005	648	8.26e-49	183
k141_26681_1	SARG|gi|446110351|ref|WP_000188206.1|	34.7	317	1005	648	8.26e-49	183
k141_26681_1	SARG|YP_002044935	38.6	293	1005	648	1.11e-48	183
k141_26681_1	SARG|gi|835666879|ref|WP_047606339.1|	38.6	293	1005	648	1.11e-48	183
k141_3814_9	SARG|L42544.gene.p01	28.2	664	692	651	2.53e-78	262
k141_3814_9	SARG|NP_348076	26.6	677	692	652	3.60e-78	261
k141_3814_9	SARG|AAV80410	28.0	664	692	651	1.32e-77	260
k141_3814_9	SARG|YP_002850805	26.0	674	692	652	5.11e-75	253
k141_3814_9	SARG|ZP_02952732	25.8	674	692	652	9.87e-74	249
k141_3814_9	SARG|ZP_02632674	25.8	674	692	660	1.16e-73	249
k141_3814_9	SARG|L20800.gene.p01	25.8	674	692	652	1.90e-73	249
k141_3814_9	SARG|FN594949.1.gene24.p01	27.2	669	692	640	1.06e-71	244
k141_3814_9	SARG|AAO42740	27.7	667	692	639	2.00e-71	243
k141_3814_9	SARG|AY485126.gene.p01	27.6	667	692	639	2.00e-71	243
k141_3814_10	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.4	131	400	639	4.71e-16	79.0
k141_3814_16	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	41.0	442	461	481	4.52e-99	304
k141_3814_16	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	41.2	437	461	451	1.05e-98	302
k141_3814_16	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	40.7	437	461	451	5.87e-98	300
k141_3814_20	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.4	435	440	444	5.11e-59	198
k141_86762_2	SARG|AAD41881	37.4	313	329	323	6.74e-59	191
k141_86762_2	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	37.9	314	329	323	2.66e-58	189
k141_86762_2	SARG|AAD51059	37.4	313	329	323	5.28e-58	189
k141_86762_2	SARG|YP_002333394	37.5	312	329	323	2.08e-57	187
k141_86762_2	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.5	312	329	323	2.08e-57	187
k141_86762_2	SARG|AF310956.2.gene5.p01	37.5	312	329	323	2.93e-57	187
k141_86762_2	SARG|KF478993.1.gene2.p01	39.9	281	329	350	3.04e-57	187
k141_86762_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	37.2	312	329	323	4.13e-57	186
k141_86762_2	SARG|Q47748	37.2	312	329	323	8.20e-57	186
k141_86762_2	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	39.6	265	329	314	9.04e-57	185
k141_38496_14	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.6	199	236	307	5.68e-15	71.6
k141_38496_14	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	26.9	186	236	494	2.20e-13	67.8
k141_38496_14	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_38496_14	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	211	236	655	2.45e-13	67.8
k141_82349_5	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.4	262	512	355	3.77e-20	90.9
k141_82349_5	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.4	262	512	355	3.77e-20	90.9
k141_82349_5	SARG|ACM47285	29.4	262	512	363	4.12e-20	90.9
k141_82349_5	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.2	260	512	355	2.24e-19	88.6
k141_82349_5	SARG|BAE96115	29.2	260	512	355	2.24e-19	88.6
k141_82349_5	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.9	251	512	356	5.52e-19	87.4
k141_82349_5	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.4	252	512	346	8.97e-19	86.7
k141_82349_5	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.5	251	512	356	2.42e-18	85.5
k141_82349_5	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.8	257	512	356	4.61e-17	81.6
k141_114404_2	SARG|gb|APB03216.1|ARO:3003982|LlmA	60.4	288	290	287	4.69e-132	375
k141_114404_4	SARG|gi|671541568|ref|WP_031525212.1|	37.4	211	283	648	1.19e-33	128
k141_114404_4	SARG|gi|657888313|ref|WP_029592374.1|	35.5	220	283	648	4.96e-32	123
k141_114404_4	SARG|gi|696368937|ref|WP_032943949.1|	34.3	236	283	648	9.22e-32	122
k141_114404_4	SARG|gi|851913025|ref|WP_048215946.1|	34.3	236	283	648	9.22e-32	122
k141_114404_4	SARG|YP_002850060	34.3	236	283	648	9.22e-32	122
k141_114404_4	SARG|gi|489930965|ref|WP_003834285.1|	34.3	236	283	648	9.22e-32	122
k141_114404_4	SARG|gi|639216333|ref|WP_024554080.1|	36.3	212	283	648	9.22e-32	122
k141_114404_4	SARG|gi|696361545|ref|WP_032936694.1|	34.3	236	283	648	1.26e-31	122
k141_114404_4	SARG|gi|489936909|ref|WP_003840216.1|	34.3	236	283	648	1.26e-31	122
k141_114404_4	SARG|gi|507079862|ref|WP_016150620.1|	34.3	236	283	648	1.26e-31	122
k141_114404_5	SARG|gi|542061059|gb|ERI11611.1|	30.1	236	292	316	3.85e-29	112
k141_114404_5	SARG|gi|445996719|ref|WP_000074574.1|	31.1	241	292	309	3.42e-28	109
k141_114404_5	SARG|gi|507044560|ref|WP_016115614.1|	31.5	241	292	306	4.50e-28	108
k141_114404_5	SARG|gi|445996710|ref|WP_000074565.1|	31.2	221	292	309	1.28e-27	107
k141_114404_5	SARG|YP_001373621	30.7	241	292	318	1.49e-27	107
k141_114404_5	SARG|gi|446026113|ref|WP_000103968.1|	31.5	241	292	306	1.68e-27	107
k141_114404_5	SARG|gi|445996696|ref|WP_000074551.1|	30.3	241	292	309	3.43e-27	106
k141_114404_5	SARG|gi|507035724|ref|WP_016107411.1|	30.3	241	292	309	4.76e-27	106
k141_114404_5	SARG|gi|445996698|ref|WP_000074553.1|	30.3	241	292	309	4.76e-27	106
k141_114404_5	SARG|gi|445996723|ref|WP_000074578.1|	30.7	241	292	309	4.76e-27	106
k141_75089_1	SARG|gb|AAV85982.1|ARO:3000535|macB	30.7	189	252	644	4.80e-23	96.7
k141_75089_1	SARG|gi|736472622|ref|WP_034494292.1|	27.2	228	252	648	7.40e-17	78.6
k141_75089_1	SARG|gi|502669352|ref|WP_012905216.1|	27.0	226	252	648	1.00e-16	78.2
k141_75089_1	SARG|gi|1035706844|ref|WP_064548272.1|	26.4	239	252	648	1.00e-16	78.2
k141_75089_1	SARG|gi|754927849|ref|WP_042284850.1|	27.4	226	252	648	1.00e-16	78.2
k141_75089_1	SARG|gi|495736522|ref|WP_008461101.1|	30.5	220	252	648	1.35e-16	77.8
k141_75089_1	SARG|gi|746243059|ref|WP_039291473.1|	30.5	220	252	648	1.35e-16	77.8
k141_75089_1	SARG|gi|746253210|ref|WP_039301529.1|	30.5	220	252	648	1.35e-16	77.8
k141_75089_1	SARG|gi|1001720867|ref|WP_061274204.1|	30.5	220	252	648	1.35e-16	77.8
k141_75089_1	SARG|gi|491270241|ref|WP_005128370.1|	27.0	226	252	648	1.83e-16	77.4
k141_75089_3	SARG|gi|498115003|ref|WP_010429159.1|	52.8	218	237	646	1.95e-73	234
k141_75089_3	SARG|gi|895898290|ref|WP_048999361.1|	52.8	218	237	646	5.37e-73	233
k141_75089_3	SARG|gi|654544841|ref|WP_028012549.1|	52.3	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|779852631|ref|WP_045348970.1|	52.8	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|836580371|ref|WP_047737758.1|	52.8	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|896106549|ref|WP_049136608.1|	52.3	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|998245120|ref|WP_061098715.1|	52.8	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|798928072|ref|WP_045906664.1|	52.8	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|746222054|ref|WP_039271209.1|	52.8	218	237	646	1.48e-72	231
k141_75089_3	SARG|gi|1022641085|ref|WP_063404331.1|	52.8	218	237	646	1.48e-72	231
k141_75089_6	SARG|gb|AAC75089.1|ARO:3003577|ugd	58.5	412	413	388	2.88e-165	468
k141_67446_4	SARG|gi|446573690|ref|WP_000651036.1|	21.9	438	464	451	2.89e-28	115
k141_67446_4	SARG|gi|686432388|ref|WP_031921070.1|	22.1	438	464	451	3.92e-28	115
k141_67446_4	SARG|gi|488374619|ref|WP_002444004.1|	24.0	438	464	452	3.97e-28	115
k141_67446_4	SARG|gi|1006223553|ref|WP_061745579.1|	21.4	434	464	451	5.33e-28	114
k141_67446_4	SARG|gi|537465183|ref|WP_020976941.1|	21.9	438	464	451	7.25e-28	114
k141_67446_4	SARG|ZP_03986195	21.9	438	464	451	7.25e-28	114
k141_67446_4	SARG|gi|446573692|ref|WP_000651038.1|	21.9	438	464	451	7.25e-28	114
k141_67446_4	SARG|gi|446573695|ref|WP_000651041.1|	21.9	438	464	451	7.25e-28	114
k141_67446_4	SARG|gi|686448604|ref|WP_031928572.1|	21.9	438	464	451	7.25e-28	114
k141_67446_4	SARG|gi|446573693|ref|WP_000651039.1|	21.9	438	464	451	9.85e-28	114
k141_174713_2	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	48.2	222	225	223	1.39e-75	226
k141_174713_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.2	222	225	229	3.68e-39	134
k141_174713_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.9	232	225	233	1.97e-36	127
k141_174713_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	225	219	1.19e-34	122
k141_174713_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	225	219	1.67e-34	121
k141_174713_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	225	220	1.72e-34	121
k141_174713_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	225	220	1.72e-34	121
k141_174713_2	SARG|ZP_02848503	32.6	224	225	221	2.48e-34	121
k141_174713_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	225	220	2.66e-33	118
k141_174713_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.4	230	225	231	6.92e-33	117
k141_43409_7	SARG|AF155139.2.gene4.p01	36.9	160	342	293	1.34e-26	105
k141_43409_7	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	37.2	137	342	299	1.93e-24	100
k141_43409_7	SARG|AAY52007	37.2	137	342	294	3.37e-24	99.4
k141_43409_7	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	37.2	137	342	296	4.81e-24	99.0
k141_43409_7	SARG|CAB61224	35.8	137	342	297	4.89e-24	99.0
k141_43409_7	SARG|gi|1025843957|ref|WP_063576302.1|	37.7	151	342	287	1.08e-23	97.8
k141_43409_7	SARG|ACP19238	35.8	137	342	296	2.40e-23	97.1
k141_43409_7	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	35.8	137	342	296	2.40e-23	97.1
k141_43409_7	SARG|AAA65958	35.8	137	342	303	2.68e-23	97.1
k141_43409_7	SARG|gi|503204183|ref|WP_013438844.1|	35.8	137	342	303	2.68e-23	97.1
k141_179112_6	SARG|gi|505420018|ref|WP_015607120.1|	30.1	239	250	603	3.81e-24	99.8
k141_179112_6	SARG|gi|695842130|ref|WP_032755430.1|	29.7	239	250	603	8.11e-23	95.9
k141_179112_6	SARG|gi|739906046|ref|WP_037756452.1|	31.4	223	250	620	1.52e-22	95.1
k141_179112_6	SARG|gi|695865802|ref|WP_032778631.1|	30.1	239	250	605	2.75e-22	94.4
k141_179112_6	SARG|gi|516574297|ref|WP_017949361.1|	31.4	223	250	620	3.78e-22	94.0
k141_179112_6	SARG|gi|947982677|ref|WP_056642336.1|	30.0	223	250	626	3.80e-22	94.0
k141_179112_6	SARG|gi|639892676|ref|WP_024755698.1|	30.0	223	250	631	3.82e-22	94.0
k141_179112_6	SARG|gi|948137056|ref|WP_056795395.1|	31.4	223	250	602	5.05e-22	93.6
k141_179112_6	SARG|gi|664244930|ref|WP_030776974.1|	30.9	223	250	601	6.84e-22	93.2
k141_179112_6	SARG|gi|1045390184|ref|WP_065479071.1|	29.7	239	250	605	6.87e-22	93.2
k141_179112_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.5	224	227	228	1.68e-52	168
k141_179112_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	46.3	177	227	219	1.06e-48	158
k141_179112_8	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.9	221	227	235	1.20e-45	150
k141_179112_8	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.0	230	227	252	6.67e-43	144
k141_179112_8	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	36.5	222	227	225	5.06e-42	141
k141_179112_8	CARD|gb|AAC73788.1|ARO:3003841|kdpE	36.5	222	227	225	5.06e-42	141
k141_179112_8	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	39.4	221	227	225	5.06e-42	141
k141_179112_8	SARG|ZP_02848503	38.4	219	227	221	2.01e-40	137
k141_179112_8	CARD|gb|AAD51348.1|ARO:3003066|smeR	37.4	222	227	229	2.18e-38	132
k141_179112_8	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.2	233	227	230	2.48e-37	129
k141_179112_9	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.4	218	556	381	3.14e-21	94.7
k141_179112_9	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.4	218	556	381	3.14e-21	94.7
k141_179112_9	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.4	218	556	381	1.02e-20	93.2
k141_179112_9	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.4	218	556	381	1.02e-20	93.2
k141_179112_9	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	273	556	381	1.85e-20	92.4
k141_179112_9	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	273	556	381	1.85e-20	92.4
k141_179112_9	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.4	213	556	885	7.00e-13	70.5
k141_43689_7	SARG|gi|748767925|ref|WP_040019608.1|	25.7	237	251	623	1.14e-11	63.2
k141_43689_7	SARG|gi|930482089|ref|WP_054228897.1|	23.9	247	251	599	9.02e-11	60.5
k141_43689_7	SARG|gi|985844137|ref|WP_060895163.1|	23.9	247	251	599	9.02e-11	60.5
k141_43689_7	SARG|gi|926400371|ref|WP_053728483.1|	28.4	176	251	603	2.95e-10	58.9
k141_43689_7	SARG|gi|953808775|ref|WP_058042812.1|	28.5	172	251	608	3.98e-10	58.5
k141_43689_7	SARG|gi|817122037|ref|WP_046494699.1|	25.3	225	251	613	7.21e-10	57.8
k141_43689_7	SARG|AF170880.4.gene1.p01	25.9	189	251	615	7.22e-10	57.8
k141_43689_7	SARG|gi|516795764|ref|WP_018105258.1|	26.5	189	251	601	9.62e-10	57.4
k141_43689_7	SARG|gi|944470764|ref|WP_055701183.1|	26.7	187	251	601	1.29e-09	57.0
k141_43689_7	SARG|gi|943896259|ref|WP_055534530.1|	26.7	187	251	601	1.29e-09	57.0
k141_118971_3	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	30.6	468	697	633	7.59e-53	192
k141_119431_2	SARG|gb|AAK76137.1|ARO:3000024|patA	25.8	221	253	564	7.15e-14	69.7
k141_119431_2	SARG|gb|AEA37904.1|ARO:3003112|lsaC	26.3	217	253	492	4.39e-12	64.3
k141_119431_2	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.6	232	253	550	7.54e-09	54.7
k141_119431_7	SARG|gi|740610794|ref|WP_038396317.1|	40.8	228	242	648	6.45e-47	163
k141_119431_7	SARG|YP_001571041	40.4	228	242	648	2.36e-46	162
k141_119431_7	SARG|gi|960873409|ref|WP_058345546.1|	40.4	228	242	648	2.36e-46	162
k141_119431_7	SARG|gi|555268367|ref|WP_023249730.1|	39.5	228	242	648	4.37e-45	158
k141_119431_7	SARG|gi|1027935297|ref|WP_063809363.1|	39.5	228	242	648	4.37e-45	158
k141_119431_7	SARG|gi|554685678|ref|WP_023185565.1|	39.5	228	242	648	4.37e-45	158
k141_119431_7	SARG|gi|959866458|ref|WP_058145168.1|	39.5	228	242	648	8.34e-45	157
k141_119431_7	SARG|gi|555246906|ref|WP_023230855.1|	39.5	228	242	648	1.15e-44	157
k141_119431_7	SARG|gi|685236936|ref|WP_031605176.1|	39.5	228	242	648	1.15e-44	157
k141_119431_7	SARG|gi|554958661|ref|WP_023203683.1|	39.5	228	242	648	1.15e-44	157
